ABSTRACT

CCCTC binding factor (CTCF) is a unique highly conserved and ubiquitously expressed 11 zinc finger (ZF) transcriptional factor with multiple target site. It is able to bind to various target sequences to perform different regulatory roles and the binding is through the combination of different ZF domains. On the other hand, BORIS (Brother of the Regulator of Imprinted Sites), which is expressed only in the testis and certain cancer cell lines is homology to CTCF 11 ZF domains. Since both transcriptional factors share the same ZF domains, hence there is a possibility for both to bind to the same target sequences. Hence, the aim of this study is to determine the in vivo interaction of CTCF and BORIS to YB-1 in the laboratory established Glioma-RGBM cell line. The protein-protein interaction between CTCF/YB-1 and BORIS/YB-1 were discovered using Co-immunoprecipitation (CO-IP) technique through reciprocal experiment in using RGBM total cell lysate. Results showed that both CTCF and BORIS were able to interact with YB-1 in RGBM cell line. To the best of our knowledge, this is the first finding demonstrating the ability of BORIS and YB-1 to form a complex in vivo.

Key words: Immunoprecipitation; CTCF/BORIS/YB-1; Transcription factor

1.0 INTRODUCTION

CCCTC binding factor (CTCF) is an 11 Zinc finger transcriptional factor with multiple DNA site specificities. It was initially identified as a transcriptional regulator (Klenova et al., 1993). It is able to bind to different target sequences to perform various regulatory roles such as promoter activation or repression, silencing and constitutive and methylation dependent chromatin insulation (Maston, et al., 2006). On the other hand, BORIS (Brother of the regulated of imprinted sites) is a paralog of CTCF. It was classified as a cancer testis antigen (CTA) and human BORIS gene spans over 29 kb at chromosome 20q13 which comprises of 11 exons, 10 of which contain coding sequences (Pugacheva et al., 2010). According to the literature, the ZF domains of both CTCF and BORIS were reported to have 95% homology however the N and C terminal domains were described to be different (Loukinov et al., 2002). This suggests that ZF regions may interact with same binding partners, but altering the gene expression probably via different mechanisms.

CTCF binds to the DNA targets either through N, ZF or C-terminal domains. Study carried out by Chernukhin et al. (2007) showed that CTCF binds to the larger subunit of RNA polymerase II (Pol II) via C terminal domain. There is another study carried out by the same group in 2000 reported CTCF formed a complex both in vivo and in vitro with YB-1 via ZF domains. In this study, CTCF was found to bind to YB-1 via the combination of different ZF domains. Since different sets of ZFs are utilized to recognize different CTCF target DNA sites, each of the diverse DNA-CTCF complexes might engage different essential protein partners to define distinct functional readouts (Mahaley et al., 1986).

YB-1 is known to participate in transcription, replication, RNA processing and DNA repair (Marshall et al., 2014). Given this properties, the interaction between CTCF/YB-1 may have functional significance roles in regulation of major cellular processes. One of the functional significance between CTCF/YB-1 identified by Chernukhin et al. (2000) is from the study of c-myc oncogene promoter (a target of CTCF) in the co-transfection study. From this study, the observation was made in which, the expression of YB-1 alone had no effects on the c-myc promoter activity, and however the co-expression of CTCF/YB-1 resulted in marked enhancement of CTCF-driven c-myc transcriptional repression.

*Corresponding author: Shaharum Shamsuddin | E-mail: shaharum1@usm.my
CTCF and BORIS expression in normal tissue are by mutually exclusive manner (Shamsi et al., 2011). Previously reported studies show that, the expression of BORIS and CTCF both could be detected in cancer cell lines. However, BORIS expression could only be detected in spermatocyte and not in the somatic cells. This is contrary to CTCF expression in which it could only be detected in somatic cell but not in spermatocyte (Figure 1.1). The switch in expression between BORIS and CTCF coincide with the re-establishment of site specific methylation patterns during male germ cell line development (Allegrucci et al., 2005). The detection of BORIS in cancer cell lines and the absence in post-meiotic germ cell line provide an opportunity to be utilized as a biomarker in cancer development.

Malignant gliomas are the most common types of brain tumours in adult and it was reported that the mean survival time of patients is less than a year (Mahaley et al., 1989). It is highly invasive and it constitutes more than 90% of all primary malignant central nervous system (CNS) tumours. Even though glioma is the major tumour in primary nervous systems, their etiology is still less understood. Hence, this study was carried out to elucidate the protein-protein interaction between CTCF and BORIS to YB-1 in glioma cell line. Previously, our group has successfully developed our in-house primary glioma cell line from local clinical tumour sample through explants technique and the cell line was named as RGBM (Recurrent Glioblastoma Multiforme). BORIS expression in this cell line was characterized and it was reported to be expressed at 76 KDa (Siti Zawani et al., 2011).

To the best of our knowledge, this is the first study reporting on the in vivo protein-protein interaction between BORIS and YB-1 in RGBM-Glioma cell line. In brief, this report is describing the association of CTCF and BORIS to YB-1. YB-1 has been identified as a protein interacting partners with CTCF. We demonstrated that, CTCF is associated in vivo with YB-1 through CO-IP (Co-Immunoprecipitation) technique. Furthermore, we show that BORIS (a paralog of CTCFL) was also able to form an in vivo complex with YB-1 via the similar technique. Hence, these findings may provide a basic link to the functional role of BORIS in the brain cancer machinery pathway.

**Figure 1.1:** BORIS and CTCF both can be detected in cancer cell line. However BORIS expression could only be detected in spermatocytes and not in somatic cells. On the other hand, CTCF expression could only be detected in somatic cell and not in spermatocyte.

2.0 MATERIALS & METHODS

2.1 Cell growth and harvesting:

For CO-IP experiment, RGBM-glioma cells were grown as monolayer in a tissue culture flask as previously described (Klenova et al., 2002). Once the desire cell density (10^7-10^8 cells) was obtained, cells were trypsinized and harvested. Cell pellet was then lysed in sucrose lysis buffer.

2.2 Cell Lysis:

Sucrose lysis buffer (10 mM Tris–HCl (pH 8.0), 10 mM NaCl, 0.3 M sucrose, 3 mM MgCl₂,0.5% NP-40) was used to total lysed the cells. Total cell lysate was incubated at 4°C overnight with gentle mixing. The supernatant was recovered the next day by centrifugation at 10,000 rpm for 10 minutes.

2.3 Co-Immunoprecipitation:

2.3.1 Pre-clearing:

For pre-clearing process, 50 µl of protein G sepharose (Calbiochem) was added into the supernatant and incubated at 4°C for 1 hr with gentle mixing on a rotating mixer. The supernatant was recovered after an hour by centrifugation at 1200g for 5 min.

2.3.2 Precipitation with antibody:

The antibodies used to precipitate the proteins of interest are listed in Figure 2.1. The exact input of
antibody required to give a moderate excess over specific antigen should be determined empirically by trial experiment. Five µl of respective antibodies were added into the pre-cleared cell lysate, incubated overnight at 4°C with gentle mixing. The following day, immune complex was recovered by centrifugation at 1200 g for 5 min. The immune complex was washed 3 times by gently resuspending in lysis buffer followed by centrifugation at 1200 g. Immune complex was then analysed by SDS-PAGE.

2.3.3 Western Blot analysis:
Immune complex was resuspended in 20µl SDS lysis buffer (60 mM Tris– HCl pH 6.8, 2% SDS, 20% glycerol, 100mM DTT and 0.02% bromphenol blue) heated at 95°C for 5 mins and analyzed on a 12% SDS-PAGE. The electrophoresed proteins were transferred onto nitrocellulose membrane using mini trans-blot apparatus (Bio-Rad, USA) according to the manufacturer’s recommendations. The blotted membrane was blocked with 5% skim milk (Sun Lac), washed three times in Tris-buffered saline (TBS) with 0.05% of Tween-20 (TBS-T) for 10 min each time and incubated with respective antibodies (Figure 2.1) in 5% blocking solution respectively for an hour at room temperature. The membrane was washed 3 times with TBS-T followed by incubation with respective secondary antibodies (Figure 2.1) for an hour at room temperature. The membrane again washed three times in TBST followed by addition of chemiluminescent substrate (Amersham) according to the suggested procedure by the manufacturer.

<table>
<thead>
<tr>
<th>Primary antibody</th>
<th>Dilution</th>
<th>Manufacture</th>
<th>Secondary antibody</th>
<th>Dilution</th>
<th>Manufacture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-YB1 monoclonal antibody (59Q)</td>
<td>1:1000</td>
<td>Santa Cruz</td>
<td>Goat antimouse</td>
<td>1:2000</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Anti-CTCF monoclonal antibody (G-8)</td>
<td>1:1000</td>
<td>Santa Cruz</td>
<td>Goat antimouse</td>
<td>1:2000</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Anti-Boris polyclonal antibody (Ab126766)</td>
<td>1:1000</td>
<td>Abcam</td>
<td>Goat antirabbit</td>
<td>1:2000</td>
<td>Santa Cruz</td>
</tr>
</tbody>
</table>

Figure 2.1: The list of primary and secondary antibodies used in this study.

3.0 RESULTS
This study was carried out to determine the in vivo protein-protein interaction between CTCF and BORIS to YB-1 in RGBM-Glioma cell line. To achieve this objective series of reciprocal CO-IP assays with RGBM-Glioma cell lysate were carried out. The total cell lysate was first precipitated with acetone to obtain a more concentrated protein before preceded with CO-IP experiment. Figure 1 shows SDS-PAGE results of RGBM total cell lysate before (lane 1) and after (lane 2) acetone precipitation.

Figure 3.1: Coomassie stained of RGBM total cell lysate was resolved in 10% SDS-PAGE. Lane M: Protein ladder; Lane 1: RGBM total cell lysate before acetone precipitation. Lane 2: RGBM total cell lysate after acetone precipitation.
Figure 2 shows CO-IP results of CTCF and YB-1 from RGBM total protein. Figure 2A (lane 1) shows the presence of CTCF protein from RGBM cell after subjected to western blot and probed with anti-CTCF antibody. Figure 2A (lane 2) shows the immunoprecipitated result of YB-1 in RGBM cell and co-migrating with YB-1 protein. The complex was resolved in SDS-PAGE and probed with anti-CTFC antibody. Result obtained shows that CTCF protein migrated at 50 KDa which coincide with the position of CTCF in unfractionated RGBM cell line. Moreover, on the reciprocal experiment, Figure 2B (lane 1) shows the presence of YB-1 protein in RGBM cell line, which migrated at 30-70 KDa after subjected to western blot and probed with anti-YB-1 antibody. Figure 2B (lane 2) shows the result of immunoprecipitated CTCF in RGBM cell co-migrating with CTCF protein. The complex was resolved on SDS-PAGE and probed with anti-YB1 antibody. The result obtained shows that, YB-1 protein migrated at 50-90 KDa which corresponded to the position of YB-1 protein in the unfractionated RGBM cell line.

**Figure 3.2:** Reciprocal experiment on *in vivo* interaction assay of CTCF/YB-1 in RGBM cell line. *In vivo* interaction assay was investigated by CO-IP followed by western blot techniques (A) Lane 1 shows the result of RGBM total protein probed with anti-CTCF antibodies whereas Lane 2 shows the result of total proteins immunoprecipitated with anti-YB1 and probed with anti-CTCF in western blot. (B) Lane 1 shows the result of RGBM total protein probed with anti-YB-1 antibodies whereas Lane 2 shows the result of total proteins immunoprecipitated with anti-CTCF and probed with anti-YB1 in western blot.

Furthermore, the interaction between BORIS and YB-1 in RGBM cell line was also determined in this study. Anti-YB-1 antibody and anti-BORIS antibody were used to precipitate the corresponding interacting proteins in the cells. Figure 3A (lane 1) shows the presence of YB-1 protein from RGBM cell after subjected to western blot and probed with anti-YB1 antibody. Whereas Figure 3A (lane 2) shows the immunoprecipitated result of BORIS in RGBM cell and co-migrating with BORIS protein. The complex was resolved in SDS-PAGE and probed with anti-YB1 antibody. Result obtained shows that, four bands of YB-1 protein could be detected and the protein migrated at 30-70 KDa. Furthermore, on the reciprocal experiment, Figure 3B (lane 1) shows the presence of BORIS protein from RGBM cell line after subjected to western blot and probed with anti-BORIS antibody. Figure 3B (Lane 2) shows the immunoprecipitated result of YB-1 in RGBM co-migrating with YB-1 protein. The complex was resolved in SDS-PAGE and probed with anti-BORIS antibody in which the protein migrated at 35 KDa and the size was coincide with BORIS protein from the unfractionated RGBM cell lysate.
4.0 DISCUSSION

The aim of this study is to elucidate the potential binding of CTCF and BORIS to YB-1. To identify such factor, we employed CO-IP technique. CO-IP is probably the most widely employed method for detecting in-vivo protein-protein interaction, particularly involving transcriptional factor complex. The advantage of this technique is that the endogenous protein complexes are studied, therefore the artificial effects of affinity tag or overexpression are avoided. From this study, we have successfully identified an interaction between CTCF and BORIS to YB-1 in RGBM cell line. Previously, Chernukhin et al. (2000) carried out a study on CTCF/YB-1 interaction in HeLa cell lysate. However so far there is no reported study on CTCF/YB-1 interaction in brain cancer cell line. Hence this is the first study reporting on CTCF/YB-1 interaction in brain cancer cell line. Chernukhin and his group reported the interaction of CTCF to YB-1 were specific against the ZFs domain and there was no interaction detected in the N and C terminal domains. BORIS on the other hand, shares the similar amino acid with CTCF in the ZFs region. Our study has successfully identified an in vivo interaction between BORIS and YB-1 in RGBM. To the best of our knowledge, this is the first study reporting on the interaction of BORIS to YB-1 in the brain cancer cell line.

Previously reported studies showed that, there are numbers of proteins could interact with CTCF. Such protein identified by Chernukhin et al. (2007) is a larger subunit pol II. In this study, K562 derived larger subunit Pol II was able to form a complex with CTCF through C domain however there is no interaction detected through ZFs and N domains. Therefore, CTCF was proven to be a diversified protein in which it is able to bind to other protein partners through specific domains. In this current study, we have successfully determined the interaction of CTCF/BORIS to YB-1, however it is important to determine whether these two proteins share the same binding region.

In this study, both CTCF and BORIS show a positive interaction to YB-1. CTCF and BORIS found to have a single band however YB-1 was detected to have few bands. From this study, YB-1 protein was detected to presence as a multi-subunit proteins and it migrated anomalously in the SDS-PAGE (Klenova et al., 2002). In CO-IP procedure, it is important to determine the integrity of the cell line and the optimum protein extraction used. For that, a control, cell lysate without the addition of appropriate antibody was included in this study. According to the research carried out by Filippova et al. (1996) BORIS expression is not uniform among the cell lines. From the study reported, breast cancer cell line was reported to have 80-100% BORIS expression whereas prostate cancer
cell line was reported to have 50-60% BORIS expression. Hence it is important to determine BORIS expression in the cancer cell line use in CO-IP procedure and in this study, BORIS expression detected was high in RGBM cancer cell line.

The presence of BORIS and CTCF in the cancer cells may interfere with the normal physiological function of the cell. Both CTCF and BORIS seem to be co-expressed in tumour cells, suggesting a potential competition between these two proteins for the same CTCF target sequences. Marshall et al., 2014 has shown that, almost 64% of BORIS binding sites are overlapping with CTCF binding sites. Therefore, incline BORIS expression, especially in the cancer cell, reduced CTCF occupancy at BORIS binding sites, indicating BORIS can compete with CTCF for the same binding region thus resulting in cellular phenotype permissive for transformation.

The conclusion, to the best of our knowledge this is the first study reported on the in vivo interaction of BORIS to YB-1. However, further experiment need to be carried out to confirm the interaction between these two proteins is direct and it is not mediated by the third protein that acts as a scaffold. For this reason in vitro interaction assay such as pull down assay can be perform to further map the interaction of these two proteins. In addition, it is also necessary to establish the functional study such as reporter assay to further understand the interaction of these two proteins as strong interactions can be non-specific and biological irrelevant whereas even weak interactions can be specific and have an important biological implication. Since BORIS expression is restricted to several cancer cells and spermatocytes, hence it could present as an immunotherapeutic avenue for the treatment of many cancers.

5.0 ACKNOWLEDGEMENT

This work was supported by the Research University Grant (RU) of Universiti Sains Malaysia (Grant number: 1001.PPSK.813074). The first author received financial support from Universiti Sains Malaysia and Ministry of Higher education Malaysia: ASTS (Academic Staff Training Scheme).

6.0 REFERENCES


